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Results. A total of 172 patients were enrolled. After a mean of 32 (0.7)
months, 165 (96%) were in follow-up, 5 (3%) patients had died (all
SSc-related deaths, but none including PH) and 1 patient (1%) was
lost to follow-up. During observation, six patients (3.5%) developed
PH confirmed by right heart catheterization. Mean DLCO (per cent
predicted) (P<0.01), DLCO/VA (%) (P<0.05), calculated RPS (0.05),
baseline and stress-induced PASP (P<0.05) or the difference
between these values (PASP) (P<0.001) measured at the study
enrolment were significantly different in patients who developed PH
(Group 1) vs those free of this complication at the end of follow-up
(Group 2). Univariate PH-free survival was significantly lower in
patients with an inappropriate increase in exercise PASP 48 mmHg
(P<0.05) or in those in the highest quintile of RPS (P<0.01). At the
multivariate Cox regression, adjusting for potential confounders, only
the value of PASP (HR¼1.2, 1.03–1.4, P<0.05) and being in the
highest quintile of RPS (HR¼13.7, 2.06–91, P<0.01) significantly
predicted survival.
Discussion. Exercise stress echocardiography identifies SSc patients
with an inappropriate response and the difference between PASP
values at rest and under stress is predictive of PH-free survival,
independently of other known clinical predictors.
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Background. Patients with SSc are at risk of developing pulmonary
hypertension. The role of exercise testing in predicting this severe
complication is still debated. Our group has recently described an
inappropriate response to exercise with particularly high (48 mmHg)
pulmonary artery systolic pressures (PASP) in a subset of SSc
patients.
Aim. To describe baseline characteristics of SSc patients with a stress
echocardiographic inappropriate response to exercise.
Methods. Patients with SSc consecutively admitted to two Italian
Rheumatology Units were enrolled if in NYHA Class I–II and showing a
peak tricuspid regurgitant jet velocity (TRV) <3 m/s at echocardio-
graphy. Clinical characterization of patients with SSc was performed
according to the European Scleroderma Trial and Research (EUSTAR)
recommendations. A risk prediction score (RPS) based on clinical
parameters was calculated as recently suggested. Baseline and stress
echocardiography were performed at both centres using similar
commercial equipments and a standard protocol until patients
experienced fatigue or symptoms, or until 85% of the age-predicted
maximum heart rate was achieved. Clinical, instrumental and
echocardiographic data were collected and analysed with SPSS
software for Macintosh (SPSS Inc, Chicago, USA).
Results. A total of 172 patients were enrolled. According to the
previously defined cut-off of exercise PASP, SSc patients were divided
into those with a value below (Group 1, n¼151) or >48 mmHg (Group
2, n¼ 21). Patients in both groups had comparable features concern-
ing sex, SSc subset and autoantibody distribution; likewise there was
no statistically significant difference in age, disease duration, mRSS,
FVC (% pred), DLCO (%) or DLCO/VA (%). Presence of interstitial lung
disease was more frequent in Group 2 than in Group 1 (62 vs 40%), but
the difference did not reach statistical significance (P¼0.06). RPS
values also did not discriminate between the two groups [3.42 (0.9)
vs 3.16 (0.82)].
Discussion. The subset of SSc patients with an inappropriate increase
in PASP detected by stress echocardiography cannot be distinguished
by any of the disease-specific features in our cohort, including
the recently described and validated RPS based on clinical observa-
tions. Longitudinal analyses might better clarify whether stress
echocardiography results are able to predict development of pulmon-
ary hypertension in SSc, representing an additional screening tool for
this severe complication.
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Background. Presence of cardiac impairments is a harbinger of poor
prognosis in the course of systemic scleroderma (SSc). Myocardial
fibrosis, considered the hallmark of cardiac involvement in SSc, is
patchy and distributed throughout the both ventricles. Fibrosis can
affect various portions of the heart conduction system, including
intraventricular His bundle. However, in numerous SSc cases, the
cardiac abnormalities can remain clinically covert. A goal of the study
was to assess diagnostic usefulness of body surface heart potential
mapping (BSPM) in detecting conduction disturbances in the patients
examined.
Material and methods. Study group consisted of 65 patients
(46 females and 19 males) with SSc (36 patients with limited SSc
and 29 with diffuse SSc) at the mean age of 51.9 (13.9) years (range
17–65 years). None of the patients presented any intraventricular
conduction abnormalities on the standard ECG recordings. BSPM
method provides multielectrode ECG recordings collected from entire
anterior and posterior thorax. The 87-lead Fukuda Denshi HPM-7100
mapping system was used to obtain isochrone maps, presenting
isolines linking the myocardial sites with the same ventricular
activation time–so-called VAT maps.
Results. First, the group-mean VAT map for the control population of
50 normal subjects was created. Both quantitative and qualitative
features, i.e. VAT maximum and minimum values and their spatial
location, of this reference map were established. Then, a precise visual
inspection of each patient’s VAT map was performed, which rendered
the three specific patterns of isochrone distribution in the SSc group.
It is worth noting that no patient’s VAT map was of normal
characteristics. Moreover, the group-mean values of VATmax and
VATmin were significantly different (P¼0.01), when the control and the
patient groups were compared. The three VAT map patterns were
classified in the SSc group as non-specific intraventricular conduction
disturbances occurring predominantly in the left (32 patients) or right
(14 patients) ventricle or in the both ventricles (19 patients).
Interestingly, the RV pattern comprised all SSc cases with definite
pulmonary hypertension (9/14) but without evident RV hypertrophy.
Conclusion. Isochrone maps obtained using the BSPM method,
showing a unique sensitivity as to changes of cardiac electric field
owing to high spatial resolution, enable to explore the early-phase
intraventricular conduction distortions in patients with systemic
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Background. b-catenin is the central integrator of canonical Wnt
signalling. Since recent evidence suggests a central role of Wnts in
fibrosis, we examined the b-catenin/Wnt pathway in SSc and focused
on the role of b-catenin in fibroblast activation.
 The Author 2012. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com
ii12
Methods. We performed qPCR for several Wnt ligands and axin-2 to
examine Wnt expression in SSc skin. We further studied protein levels
of Wnt-1, -4, -10b and b-catenin by IHC. To establish the effects of
b-catenin/Wnt signalling on collagen release, we created mice with
fibroblast-specific stabilization of b-catenin (dEx3 b-catenin (wt/
fl)Col1a2; Cre-ER) as well as mice carrying fibroblast-specific
deletion of b-catenin [Ctnnb1(fl/fl)Col1a2; Cre-ER].
Summary of the results. We could demonstrate mRNA overexpres-
sion of Wnt-1, -2, -9a, -9b, -10a, -10b and -16 in SSc skin. Wnt-1, -4
and -10b consistently showed strong expression in SSc skin when
compared with healthy skin. On protein level, however, Wnt-4 was
indistinguishable between SSc patients and healthy controls, whereas
Wnt-1 and Wnt-10b protein levels were increased in SSc skin. The
overexpression of Wnt-1 and Wnt-10b resulted in a prominent nuclear
accumulation of b-catenin in fibroblasts. Finally, increased mRNA
levels of the target gene axin-2 confirmed the activation of canonical
Wnt signalling.
In dEx3 b-catenin (wt/ex) mice, we addressed the consequences
of enhanced Wnt signalling and increased accumulation of b-catenin in
SSc. We selectively targeted b-catenin in fibroblasts. Cre-activated
dEx3 b-catenin (wt/fl)Col1a2; Cre-ER mice showed massive and
spontaneous dermal thickening even 2 weeks after Cre activation.
Eight weeks after Cre-activation, skin thickening cumulated at 102.6%
(P<0.001). In line with the dermal thickening, hydroxyproline content
and myofibroblast counts showed strong increases.
To test the therapeutic potential of targeting b-catenin/Wnt signaling,
we created Ctnnb1(fl/fl) x Col1a2;Cre-ER mice to specifically delete b-
catenin in fibroblasts. After Cre activation and b-catenin deletion in
fibroblasts, mice were challenged with bleomycin subcutaneously for 4
weeks. We found that Cre-activated Ctnnb1(fl/fl)Col1a2; Cre-ER
mice were protected from bleomycin-induced dermal with a reduction
of skin thickening by 71% (P<0.05).
Conclusions. We demonstrated a prominent activation of canonical
Wnt signalling in SSc with nuclear accumulation of b-catenin in
fibroblasts and activation of the target gene axin-2. Our results showed
that fibroblast-specific stabilization of b-catenin resulted in enhanced
collagen release, whereas deletion of b-catenin potently reduced
collagen production. Together, our findings highlight a key role of
b-catenin in fibroblast activation and fibrosis. Thus, b-catenin may be
promising molecular target for anti-fibrotic therapies.
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Background. Uncontrolled activation of fibroblasts releasing large
amounts of extracellular matrix proteins is a key feature of SSc. Janus
kinase 2 (JAK2) is an important mediator of cytokine signalling and
mutations in the JAK2 gene have been identified in the molecular
pathogenesis of myeloproliferative diseases.
Methods. Immunohistochemistry for pJAK2 served as marker for
pathway activation. Dermal fibroblasts were stimulated with TGF-b
and incubated with the specific JAK2 inhibitor TG 101209. The anti-
fibrotic potential of a specific JAK2 inhibition in vivo was evaluated in
bleomycin-induced dermal fibrosis and tight-skin 1 (Tsk-1) mice.
Results. Increased and prominent accumulation of pJAK2 was
observed in fibroblasts in skin of SSc patients and in cultured SSc
fibroblasts. Inhibition of JAK2 in SSc fibroblasts by the selective JAK2
inhibitor TG 101209 or by siRNA decreased the formation of stress
fibres by 41 (5)%, the expression of aSMA by 41 (6)% and the basal
mRNA levels of col 1a1 and col 1a2 by 59 (4)% and 51 (3)% (P< 0.05
each). These inhibitory effects in the absence of exogenous stimulation
were not observed in healthy dermal fibroblasts. Stimulation of healthy
fibroblasts with TGF-b increased time-dependently the levels of
pJAK2. Pre-incubation with TG 101209 abrogated the stimulatory
effects of TGF-b with decreases in stress fibre formation by 74 (12)%,
aSMA expression by 84 (11)% (P< 0.05) and reduced col 1a1 and col
1a2 mRNA levels by 90 (21)% and 92 (14)% (P<0.05). Consistently,
inhibition of JAK2 exerted potent anti-fibrotic effects in experimental
fibrosis. In the model of bleomycin-induced fibrosis, treatment with
TG 101209 decreased dermal thickening by 95 (5)% (P¼0.007),
hydroxyproline content by 76 (7)% (P< 0.001) and myofibroblast
counts completely back to baseline levels (P¼0.001). Application of
TG 101209 in Tsk-1 mice reduced hypodermal thickening, hydroxypro-
line content and myofibroblast counts by 82 (10)% (P¼ 0.002), 75
(25)% (P¼0.03) and 99 (13)% (P¼0.01).
Conclusion. We demonstrate that JAK2 is activated in SSc in a TGF-
b-dependent manner and mediates the stimulatory effects of TGF-b on
fibroblasts. As inhibitors of JAK2 are currently evaluated in clinical
trials for myeloproliferative disorders and are well tolerated, our
findings might stimulate clinical trials with JAK2 inhibitors in SSc
patients.
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Background. Aberrant activation of the canonical Wnt pathway has
been implicated in a variety of different diseases. To avoid uncon-
trolled activation, Wnt signalling is tightly controlled by endogenous
inhibitors such as dickkopf-1 (Dkk-1). Here, we investigated the
interaction between TGF-b-dependent pathways and canonical Wnt
signalling in SSc.
Results. Canonical Wnt signalling is activated in SSc with nuclear
accumulation of b-catenin, the central mediator of canonical Wnt
signalling, and increased expression of the target gene axin-2. The
activation of canonical Wnt signalling in SSc is mediated at least in part
by TGF-b. TGF-b decreases the levels of the endogenous inhibitor
Dkk-1 in a p38-dependent manner by >80%. The expression of Dkk-1
is almost undetectable in the skin of SSc patients and in different
models of experimental models of fibrosis. TGF-b potently activated
canonical Wnt signalling in vitro and in vivo with nuclear accumulation
of b-catenin, increased TOP-reporter activity and induction of axin-2
mRNA. In contrast, inhibition of TGF-b-signaling in experimental
models of fibrosis by SD-208, a selective inhibitor of TGF-b receptor
kinase activity, strongly decreased the activation of canonical Wnt-
signalling, thereby highlighting the key-role of TGF-b for the activation
of Wnt signalling in fibrosis. The activation of Wnt signalling directly
contributes to the pro-fibrotic effects of TGF-b. Canonical Wnt
signalling stimulates the release of collagen in vitro and induces
massive fibrosis in vivo. Recombinant Dkk-1 strongly reduced the
stimulatory effects of TGF-b and decreased the TGF-b-induced up-
regulation of collagen, aSMA and stress fibres by up to 75%.
Moreover, transgenic overexpression of Dkk-1 ameliorates fibrosis in
mice induced by adenoviral transfection of constitutively active TGF
receptor type I with reduction of dermal thickening, myofibroblast
counts and hydroxyproline content by up to 85 (5)%. Overexpression
of Dkk-1 also exerted potent anti-fibrotic effects in bleomycin-induced
dermal fibrosis and in Tsk-1 mice.
Conclusions. TGF-b activates canonical Wnt signalling in SSc by
decreasing the expression of the Wnt inhibitor Dkk-1. The activation of
canonical Wnt signalling directly contributes to the profibrotic effects
of TGF-b and potently induces fibroblast activation and tissue fibrosis.
Overexpression of Dkk-1 significantly decreases the pro-fibrotic
effects of TGF-b and prevents fibrosis in different experimental
models, demonstrating that the interaction of the canonical Wnt
pathway and TGF-b plays a key role in the pathogenesis of fibrotic
diseases.
S.6.4 INHIBITION OF FOCAL ADHESION KINASE PREVENTS
EXPERIMENTAL LUNG FIBROSIS AND MYOFIBROBLAST
FORMATION
D. Lagares1, O. Busnadiego1, R. Garcia-Fernandez2, M. Kapoor3,
S. Liu3, D. Carter4, D. Abraham5, X. Shi-Wen5, P. Carreira6,
B. Fontaine7, B. Shea7, A. Tager7, A. Leask3, S. Lamas1 and
F. Rodriguez-Pascual1
1Centro de Biologı´a Molecular Severo Ochoa and Laboratorio
Mixto Consejo Superior de Investigaciones Cientı´ficas, 2Universidad
Complutense de Madrid (UCM), Madrid, Spain, 3Schulich School
of Medicine and Dentistry, University of Western Ontario,
4London Regional Genomics Centre, London, Canada,
5University College London, London, UK, 6Hospital Universitario 12
de Octubre, Madrid, Spain and 7Massachusetts General Hospital,
Boston, USA.
 The Author 2012. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com
ii13
Tissue fibrosis caused by pathological activation of fibroblasts with
increased synthesis of extracellular matrix components is a major
hallmark of SSc. Focal adhesion kinase (FAK), an essential component
in the extracellular matrix-mediated adhesive signalling, was found to
be hyperactivated in lesional scleroderma fibroblasts, and therefore
this kinase has been hypothesized to be a key mediator of this
disease. The present study was undertaken to investigate the role of
FAK signalling in SSc and to evaluate the therapeutic potential of FAK
inhibition for the treatment of lung fibrosis. FAK activity and expression
is up-regulated in lungs of mice subjected to non-infectious injury and
in human idiopathic pulmonary fibrosis (IPF) or scleroderma (SSc)
patients as investigated by immunohistochemistry (IHC). Genetic or
pharmacological targeting of FAK abrogates fibrogenesis in the
bleomycin-induced lung fibrosis model as quantitated by IHC and
collagen content. In vitro, FAK activation is required for endothelin-1-
induced myofibroblast differentiation, extracellular matrix (ECM)
production and contractility as tested by western blot, real-time PCR
and gel contraction assay. These results implicate FAK as a central
mediator of fibrogenesis, and highlight this kinase as a potential
therapeutic target in fibrotic diseases. These findings might have direct
translational implications because different inhibitors of FAK are
available and have yielded promising results in cancer trials.
SESSION 7
MUSCULOSKELETAL
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Background. Articular involvement is a common feature of SSc with
major impact on quality of life. However, assessment is frequently
difficult, as clinical assessment is limited by concomitant skin
involvement and X-ray cannot capture tendon damages. Therefore,
the prevalence and characteristics of joint involvement are imperfectly
known. Ultrasonography (US) has demonstrated its major input in
other rheumatic conditions but only scarce data are available in SSc.
Therefore, we set out to investigate ultrasonographic hand and wrist
features in consecutive SSc patients and their relationships with
clinical examination, biological and radiographic data.
Materials and methods. A total of 52 consecutive SSc were included
in a cross-sectional observational study and in addition 24 patients
with RA were enrolled as controls. All the patients underwent clinical
examination. Global disability was assessed using the HAQ and the
Duruoz Hand Index. US was performed on joints of both hands, both
wrists and fingers. The following predefined features were searched
for: synovitis, tenosynovitis, acro-osteolysis, calcinosis, power
Doppler in the nail bed and in the pulp. Radiographies of the hands
and wrists were also performed. Data were statistically analysed using
chi-square tests and the Student’s t-test. A multivariate, step-wise
logistic regression analysis was also performed for all variables
identified with P< 0.10. P< 0.05 was considered statistically
significant.
Results. The characteristics of SSc patients were: mean age: 56.3
(14.1) years, 75% were women, mean disease duration: 8.6 (8.6) years,
40% fulfilled diffuse cutaneous subtype. Prevalences of US abnorm-
alities in SSc patients were as follows: synovitis in 46%, tenosynovitis
in 27%, calcifications in 40%, acro-osteolysis in 19% and impairment
in the distal microvascularization in 44%. Synovitis were in 57% of
cases mildly inflammatory (Doppler Grade 1), whereas tenosynovitis
showed a mixed pattern associating both inflammatory and fibrotic
changes. As compared with RA patients, US hand features specific to
SSc were ‘sclerosing’ tenosynovitis (P<0.01), soft-tissue calcifica-
tions (P¼0.01) and impairment in the distal microvascularization
(P<0.01). US detected 31 and 21% more patients with synovitis and
tenosynovitis, respectively, than clinical examination. In multivariate
analysis, a CRP level superior to 10 mg/l was associated with
inflammatory activity at power Doppler assessment (P¼0.03).
Conclusion. Our study confirms that articular involvement in SSc is
frequent and under-estimated by clinical examination. It is character-
ized by mild inflammatory damages associated with biological
inflammatory syndrome and with US sclerosing findings for tenosy-
novitis. Further prospective studies are warranted to evaluate the
predictive value of these findings.
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Background. The absence of a serum test predictive of activity or
severity in Scleroderma (SSc) is a major burden both for clinical
intervention studies and for clinical management. Recently, a large
multicentre study has identified an algorithm of three serum
biomarkers as predictive of severity and clinical outcome in chronic
liver disease. The algorithm, known as Enhanced Liver Fibrosis (ELF),
includes the measurement of serum concentrations of hyaluronic acid,
TIMP-1 and aminoterminal propeptide of procollagen Type III.
Objective. To evaluate the predictive value of ELF test as surrogate
outcome measure of fibrosis in SSc.
Methods. A total of 210 SSc patients were enrolled in the study. All
patients were investigated for clinical and serological subset, disease
duration (d.d.), vascular, skin, joint, tendon, muscle, oesophago-
gastrointestinal, lung, heart and kidney involvement, disease severity,
disease activity and HAQ-DI. ELF score was determined blindly by an
independent commercial service (iQur, London, UK). Correlations were
calculated using Spearman’s correlation test. Mann–Whitney test was
used to perform comparison between groups. All the variables found
to be correlated in univariate analysis were subsequently assessed by
step-wise regression analysis. Data were analysed using SPSS18
software.
Results. The mean ELF score in SSc patients sera was 8.71 (1). ELF
score significantly correlated with: mRSS (r¼ 0.28; P<0.0001), FVC
(r¼0.16; P¼0.0287), DLCO (r¼0.32; P<0.0001), EScSG-Activity
Index (r¼ 0.23; P¼ 0.02), total Medsger’s disease severity score
(r¼0.3; P< 0.0001) and severity score of skin (r¼ 0.31; P<0.0001),
joint/tendon (r¼0.23; P¼ 0.0007), muscle (r¼ 0.27; P<0.0001), GI
tract (r¼0.17; P¼0.0144), heart (r¼0.22; P¼ 0.0011), HAQ-DI
(r¼0.32; P<0.00001), ESR (r¼ 0.25; P¼0.0003), age (r¼0.41;
P<0.0001). Step-wise regression analysis identified mRSS (standar-
dized b¼0.299, P<0.0001), age (standardized b¼0.289, P¼0.001),
DLCO (standardized b¼0.245, P¼0.004) and gender (standardized
b¼ 0.235, P¼ 0.005) as independently associated with ELF score. The
median ELF score was significantly higher in patients with dcSSc
enrolled within the first year of the disease than in age-/gender-
matched lcSSc patients with >5 years d.d. (P¼0.0152) and not
significantly higher when compared with matched dcSSc with >3
years d.d. The median ELF score was higher in SSc patients with chest
HRCT fibrosis and DLCOFVC <80% predicted value, than in SSc
controls matched for age, gender, subset, mRSS and d.d.
(P¼0.0079).
Conclusion. The ELF test is a simple serum test that significantly
correlates with several measures of fibrosis in SSc. It has a clear face
validity for measuring the concentration of molecules involved in
extracellular matrix turnover and correlates with fibrotic severity and
activity in SSc. ELF test should be considered as outcome measure in
clinical trials.
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